Sanofi SA
SAN: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€437.00 | Rkj | Qzdhylnc |
Sanofi Earnings: Solid Results, Led by Well-Positioned Dupixent and Strong Beyfortus Launch
Sanofi reported solid fourth-quarter 2023 earnings slightly ahead of our expectations, but we aren't making any fair value estimate changes based on the minor outperformance. We still view the stock as undervalued with the market unlikely to be fully appreciating the firm’s strong position in immunology, which also gives us confidence in its wide moat.